Kyfora Bio, a new bioprocessing brand by Polysciences, is dedicated to supporting the development of cell and gene therapy (CGT) breakthroughs from bench to clinic. Leveraging over 60 years of specialty chemical development, manufacturing, and application expertise, Kyfora Bio provides research-grade through cGMP transfection reagents and excipients for viral vectors, mRNA vaccines, and other drug delivery applications. Our cost-effective and scalable cGMP processes empower advanced therapies to improve patients' lives.
Our Mission
At Kyfora Bio, our mission is to empower the development and commercialization of advanced therapies that improve patient outcomes. By providing high-quality, scalable, and cost-effective bioprocessing solutions, we aim to be a trusted partner in the cell and gene therapy industry.
Our Commitment
Kyfora Bio represents Polysciences' renewed dedication to becoming the preferred provider of essential cGMP-compliant materials for the cell and gene therapy industry. With over 60 years of expertise in chemical synthesis, combined with our cutting-edge manufacturing facility and 210/211 compliant quality management system, we are well-equipped to help our clients deliver life-saving therapies to patients. Our adaptable CDMO business model and extensive technical knowledge make us the ideal partner for those needing development and manufacturing of innovative materials for research, clinical trials, and commercial biotherapeutic production.
Our Expertise
Building on Polysciences' extensive experience in developing and manufacturing monomers, polymers, microspheres, and specialty reagents for the medical device, diagnostic, and pharmaceutical industries, Kyfora Bio focuses on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
